A Pittsfield-based biotech company recently announced a pair of partnerships with businesses in California and Canada.Nuclea Biotechnologies is now partnering with the Institut de recherches cliniques de Montréal to develop new tests to determine if certain types of insulin work for people with type 2 diabetes. Nuclea CEO Pat Muraca says people can be insulin-resistant or need a specific type, factors that can delay treatment.
“We will be able to have a diagnostic test that will help type 2-diabetics get on the right medication at the right time,” said Muraca.
Nuclea is also partnering with Aelan Cell Technologies of San Francisco to look at how genes age and what biomarkers can be used to diagnose diseases faster. Muraca says the partnerships mark Nuclea’s move from research to development.
